Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
2(100.0%)
2Total
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT04874064Recruiting

TRIple Negative Breast Cancer Markers In Liquid Biopsies Using Artificial Intelligence

Role: collaborator

NCT02355171Suspended

Personalize My Treatment (PMT) Registry

Role: lead

NCT04564079Completed

An Observational Study to Evaluate the Clinical Utility of the Oncomine Precision Assay Within the Exactis Network

Role: lead

NCT05358639Phase 1Active Not Recruiting

Combination of Olaparib and Navitoclax in Women with HGSC and TNBC

Role: collaborator

NCT04409925Phase 1Completed

DISmantling COvid iNduced Neutrophil ExtraCellular Traps (DISCONNECT-1)

Role: collaborator

NCT01276899Completed

Study to Identify Molecular Mechanisms of Clinical Resistance to Chemotherapy in Triple Negative Breast Cancer Patients

Role: collaborator

NCT04566458Completed

RWD Study in HER2+ mBC Patients in Third-Line Therapy

Role: lead

NCT00984048Completed

Study to Identify Mechanisms of Resistance to Standard Therapy in Patients With Metastatic Colorectal Cancer

Role: collaborator

All 8 trials loaded